SPROUTY-2 (SPRY2) is a modulator of tyrosine kinase receptor signaling with receptor-and cell type-dependent inhibitory or enhancing effects. Studies on the action of SPRY2 in major cancers are conflicting and its role remains unclear. Here we have dissected SPRY2 action in human colon cancer. Global transcriptomic analyses show that SPRY2 downregulates genes encoding tight junction proteins such as claudin-7 and occludin and other cell-to-cell and cell-to-matrix adhesion molecules in human SW480-ADH colon carcinoma cells. Moreover, SPRY2 represses LLGL2/HUGL2, PATJ1/INADL and ST14, main regulators of the polarized epithelial phenotype, and ESRP1, an epithelial-to-mesenchymal transition (EMT) inhibitor. A key action of SPRY2 is the upregulation of the major EMT inducer ZEB1, as these effects are reversed by ZEB1 knock-down by means of RNA interference. Consistently, we found an inverse correlation between the expression level of claudin-7 and those of SPRY2 and ZEB1 in human colon tumors. Mechanistically, ZEB1 upregulation by SPRY2 results from the combined induction of ETS1 transcription factor and the repression of microRNAs (miR-200 family, miR-150) that target ZEB1 RNA. Moreover, SPRY2 increased AKT activation by epidermal growth factor, whereas AKT and also Src inhibition reduced the induction of ZEB1. Altogether, these data suggest that AKT and Src are implicated in SPRY2 action. Collectively, these results show a tumorigenic role of SPRY2 in colon cancer that is based on the dysregulation of tight junction and epithelial polarity master genes via upregulation of ZEB1. The dissection of the mechanism of action of SPRY2 in colon cancer cells is important to understand the upregulation of this gene in a subset of patients with this neoplasia that have poor prognosis.
INTRODUCTION SPROUTY-2 (SPRY2) belongs to a family of intracellular modulators of tyrosine kinase receptor signaling.
1,2 SPRY2 action is receptorand cell type-dependent: it inhibits signaling by activated fibroblast growth factor receptor and vascular endothelial growth factor receptor, whereas it increases signaling by epidermal growth factor receptor in some cell types. 3, 4 The underlying mechanisms include the inhibition of epidermal growth factor receptor ubiquitination-dependent degradation and trafficking from early to late endosomes. 5, 6 Given the important role of epidermal growth factor receptor and fibroblast growth factor receptor on the biology of many epithelial cell types and as therapeutic targets in carcinomas and other cancers, SPRY2 is drawing increasing attention. However, the role of SPRY2 in cancer remains unclear. 2 In colon cancer, we have previously reported SPRY2 upregulation in high-grade tumors and at the invasion front of low-grade tumors. 7 Similarly, SPRY2 RNA and protein levels are higher in colon adenocarcinomas than in normal adjacent mucosa. 8 In SW480-ADH colon cancer cells, SPRY2 represses CDH1/E-cadherin and counteracts the adhesive phenotype induced by 1α,25-dihydroxyvitamin D 3 . 7 Moreover, in HT-29 and LS-174T cells SPRY2 increases the level of c-MET and hepatocyte growth factor-stimulated extracellular signal-regulated kinase (ERK) and AKT phosphorylation, promoting cell migration and invasion. 8 Further supporting a tumorigenic role, SPRY2 is upregulated in K-RAS mutant colorectal cancer, 9 and in melanoma cells harboring N-RAS or B-RAF mutations. 10, 11 RNA expression repository databases show upregulation of SPRY2 expression in colorectal tumors vs others neoplasias. 12 Consistently, we have recently shown that SPRY2 is a target of β-catenin/FOXO3a, a marker of poor prognosis in colon cancer. 13 In contrast, lower levels of SPRY2 RNA have been reported in tumor vs normal tissue and in stage III/IV vs stage II colon cancer patients, as well as inhibitory effects of exogenous SPRY2 overexpression on the proliferation, migration and tumorigenic potential of HCT116 colon cancer cells xenografted in immunodeficient mice.
Also, SPRY2 appears to have tumor-suppressive effects in breast, prostate and liver cancers and in B-cell diffuse lymphoma. [15] [16] [17] [18] [19] These opposite effects are indicative of cell type-dependent activities of SPRY2. 2 To dissect the action of SPRY2 in colon cancer, we analyzed its effects on gene expression and phenotype of SW480-ADH cells. Transcriptomic analyses revealed the repression by SPRY2 of genes encoding proteins involved in cell-to-cell and cell-to-matrix adhesion or regulating epithelial cell polarity such as ST14, which codes for the membrane-anchored serine protease matriptase that is essential for the integrity of the intestinal epithelial barrier. 20 We show that most of the gene regulatory effects of SPRY2 are mediated by ZEB1, a major epithelial-to-mesenchymal transition (EMT) inducer. Thus, SPRY2 is a potent inhibitor of the epithelial phenotype in colon carcinoma cells by repressing tight junction and polarity regulators through the upregulation of ZEB1, which in turn results from the induction of the transcription factor ETS1 and the downregulation of micro(mi)RNAs (miR200 family, miR-150) that target ZEB1 RNA.
RESULTS

SPRY2 represses epithelial adhesion and polarity genes
To characterize the effects and dissect the mechanism of action of SPRY2 in colon carcinoma cells, we generated SW480-ADH cells (containing low level of endogenous SPRY2 protein) stably expressing a wild-type (AU5-tagged) SPRY2 (SPRY2-wt cells). We also generated cells expressing mutant S112A (SPRY2-S112A cells) or Y55F (SPRY2-Y55F cells) SPRY2 proteins, which respectively lack the phosphorylation site for Mnk1/2 kinases (Ser 112 ) or a tyrosine residue (Tyr 55 ) thought to be required for the interaction with c-Cbl and thus for potentiation of epidermal growth factor receptor stability, as well as for full fibroblast growth factor inhibitory activity. [21] [22] [23] [24] Empty vector transfected cells (Mock) were used as control. All cell types had a similar polygonal morphology except SPRY2-Y55F cells that appeared more elongated (Figure 1a , left). Expression of exogenous SPRY2 proteins was confirmed by western blot (Figure 1a, right) .
To get insight into the mechanisms through which SPRY2 impacts on gene expression, we carried out a global transcriptomic analysis of the four transfectants. High correlation was observed between replicates (Supplementary Table 1) , whereas SPRY2-wt and SPRY2-S112A have the lowest correlations between conditions. Samples were unambiguously clusterized by transfected type in a principal component analysis explaining most of the variance (99.7%) (Supplementary Figure S1) . Furthermore, single enrichment analysis with differentially expressed transcripts (Supplementary Table 2) showed that genes related with cell-to-cell and cell-to-matrix adhesion were highly represented in the comparisons except for Mock vs SPRY2-S112A (Supplementary Table 3 ). These findings were also supported by a gene set enrichment analysis (GSEA) on adhesion-related Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathways (Figure 2 ). Our previous studies showed the capacity of SPRY2 to inhibit the expression of CDH1/E-cadherin causing loss of intercellular adhesion. 7 In addition, SPRY2 is preferentially expressed in cells at invasion front of human colon tumors in vivo. 7 These results, together with data from in silico analyses, led us to perform a detailed inspection of genes related to adhesion structures and pathways.
As compared with Mock cells, SPRY2-wt cells showed lower expression levels of genes encoding adherens junctions proteins (CDH1, CDH3), tight junctions proteins (CLDN7/claudin-7, OCLN/ occludin) and other adhesion molecules (GJB2, NCAM, JUP/CTNNG) (Supplementary Table 2 ). Conversely, SPRY2-wt cells expressed higher level of ZEB1 and CLDN1/claudin-1, which has been proposed to be protumorigenic in colon cancer.
25 SPRY2-wt cells showed also reduced expression of several genes encoding integrins (ITGB8, ITGB4, ITGB2 and ITGB6) and extracellular matrix proteins (TNC, LAMB3, LAMC2 and LAMA3). Downregulation of CLDN7 and OCLN and upregulation of CLDN1 and ZEB1 in SPRY2-wt and SPRY2-Y55F cells were validated by quantitative real-time PCR (qRT-PCR) and western blot (Figures 1b and c) , using the reported inhibition of CDH1/E-cadherin as control. 7 GSEA revealed that the expression profiles of genes encoding adhesion and extracellular matrix proteins were significantly enriched in SPRY2-S112A cells and Mock cells compared with SPRY2-wt ( Figure 2 ).
Further supporting a role of SPRY2 disrupting tight junction functionality and cell polarity, our transcriptomic study showed also reduced expression in SPRY2-wt and SPRY2-Y55 cells of LLGL2/HUGL2, PATJ1/INADL and ST14, polarity genes that promote tight junction formation and function as tumor suppressors (Supplementary Table 2 and Figures 1d and e) . 20, [26] [27] [28] SPRY2 represses also epithelial cell adhesion molecule (EPCAM) gene that is mutated in a proportion of hereditary non-polyposis colorectal cancer patients and whose overexpression has tumor type-dependent effects on patient survival (Figures 1d and e) . 29 EpCAM protein binds claudin-1 and claudin-7 and regulates their dynamics and the function of tight junctions. 30, 31 Epithelial splicing regulatory protein 1 (ESRP1), which encodes a broad splicing regulator in epithelial cells that prevents the EMT process, 32, 33 was strongly downregulated in SPRY2-wt cells and, conversely, upregulated in SPRY2-S112A cells (Figure 1d) . Consistent with the findings described above, the expression levels of ZEB1 and SPRY2 proteins directly correlate in a panel of colon carcinoma cell lines (Supplementary Figure S2) . Collectively, these results indicate that SPRY2 ectopic expression causes loss of the epithelial phenotype (adhesiveness and polarity) by controlling multiple genes, and highlight the importance of Ser 112 for this function. To investigate how SPRY2 regulates tight junction genes, we cloned a fragment of CLDN7 proximal promoter (−1136/+428 bp) upstream the luciferase reporter gene. Overexpression of SPRY2 markedly reduced the activity of CLDN7 promoter (Figure 1f ). ZEB1 is a major inducer of EMT that represses a number of epithelial adhesion genes. We found an inverse relation between the expression level of claudin-7 and ZEB1 proteins in the four cell types (Figure 1c) . Interestingly, ectopic expression of ZEB1 inhibited CLDN7 promoter in Mock cells but did not further decrease its activity in SPRY2-wt cells, which is consistent with the high level of ZEB1 expression in the latter cells (Figure 1f ). This supports a major role of ZEB1 in the repression of CLDN7 by SPRY2. Statistical analysis was determined by one-way ANOVA using Tukey-Kramer post-test (*Po0.05; **Po0.01; ***Po0.001; n.s., not significant).
ZEB1 mediates the repression of epithelial adhesion and polarity genes by SPRY2 Given that ESRP1, LLGL2/HUGL2 and ST14 genes are repressed by ZEB1 in other systems, [34] [35] [36] (Figure 3a) . Data on claudin-7, E-cadherin, ST14 and EpCAM were reproduced at the protein level ( Figure 3b ). In agreement with the reciprocal negative feedback loop of regulation described in other systems, 37-39 ZEB1 knock-down caused the upregulation of miR-200b and miR-200c ( Figure 3c ). Similar results were obtained in SPRY2-wt cells in which ZEB1 was silenced by lentivirus transduction of ZEB1 shRNA (Figures 3d-f) . Moreover, interference expression of ZEB1 in SPRY2-wt cells induced CLDN7 and CDH1 promoters ( Figure 3g ). Identical results were obtained by using lentiviruses to knock-down ZEB1 expression in Mock cells (Supplementary Figure  S3) . These results strongly suggest that ZEB1 mediates the dysregulation of tight junction and epithelial polarity genes by SPRY2 and that ZEB1 is a probable direct repressor of claudin-7. Figure 2 . Mock-and SPRY2-S112A-cell signature predicts cellular adhesion vs SPRY2-wt signature. Genes are ranked according to their differential expression between Mock vs SPRY2-wt cells (left), SPRY2-S112A vs SPRY2-wt cells (middle), Mock vs SPRY2-S112A cells (right). GSEA results for the enrichment of this gene set (GEO accession: GSE56941) detected toward the data sets: adherens junctions (KEGG pathways), intercellular junctions (GO: 0005911) and cell-to-cell and extracellular matrix junctions as 'cell junctions' (GO: 0030054). Black bars below the graph depict the position of genes significantly enriched. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate; NS, not significant. . Statistical analysis was determined by one-way ANOVA using Tukey-Kramer post-test (*Po0.05; **P o0.01; ***P o0.001; n.s., not significant).
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Inverse correlation between the expression of SPRY2 and ZEB1 with that of claudin-7 in colon tumors To explore the relevance of these findings in vivo, we analyzed the expression of SPRY2, ZEB1 and claudin-7 in tissue microarrays of tumors of colon cancer patients (Figure 4a ). Significant positive correlation between the expression of SPRY2 and ZEB1 (n = 39, r = 0.63, P o0.0001) and negative correlation between that of ZEB1 and claudin-7 (n = 53, r = -0.36, P = 0.007) and SPRY2 and SPROUTY-2 induces ZEB1 and EMT in colon cancer cells A Barbáchano et al claudin-7 (n = 34, r = -0.35, P = 0.037) were found ( Figure 4b ). These results were consistent with those obtained in cultured cells supporting the idea that the regulation of ZEB1 by SPRY2 and the repression of claudin-7 by ZEB1 occur also in vivo in human colon tumors.
Mechanism of ZEB1 upregulation by SPRY2
To investigate the mechanism of ZEB1 upregulation by SPRY2, we first studied whether this effect could be mediated by the modulation of miRs targeting ZEB1 RNA. An in silico analysis of ZEB1-RNA-3′UTR region using three independent target prediction . Statistical analysis was determined by one-way ANOVA using TukeyKramer post-test (*P o0.05; **P o0.01; ***P o0.001; n.s., not significant).
algorithms (TargetScan, miRANDA and PicTar) revealed the presence of several putative binding sites for evolutionarily conserved miR species: miR-142-3p, miR-23, miR-150, miR-342-3p and the previously described miR-200b/c 37-39 ( Figure 5a ).
To examine the role of these miRs in ZEB1 RNA regulation by SPRY2, their expression was analyzed by qRT-PCR in Mock and SPRY2-wt cells. miR-142-3p, miR-23a and miR-150, and also miR-200b, miR-200c, but not miR-342-3p, were expressed at lower (Figure 5b ). Reduced expression of miR-200b and miR-200c was also detected in SPRY2-Y55F cells, but not in SPRY2-S112A cells (Figure 5c ). To determine whether these miRNAs directly modulate ZEB1 levels, we cloned a fragment of ZEB1-RNA-3'UTR containing the putative miRNA-binding sites into the psiCHECK2 dual luciferase reporter vector. Co-transfection of HEK293T cells with mimic oligonucleotides of miR-200b, miR-142-3p and miR-150, but not miR-23a, together with a ZEB1-RNA-3'UTR-luciferase construct, resulted in reduced luciferase activity at both low (5 nM) and high (50 nM) amount of transfected oligonucleotides (Figure 5d) . (Figures 5f and g ). Consistently, only miR-200b led to upregulation of claudin-7 and E-cadherin (Figure 5g) . These results show a preferential regulation of ZEB1 RNA by miR-200 and an additional effect of miR-150, and support that the repression of claudin-7 by SPRY2 is mediated by ZEB1.
To examine whether SPRY2 could control directly the expression of miR-200b/c, we used luciferase-reporter vectors containing the promoter of miR-200b/a (miR-200b-a-429 (-321/+120)) 40 and miR-200c (hsa-miR-200c promoter (-683/-67)). 39 First, these plasmids were transfected into Mock and SPRY2-wt cells. A stronger reduction in the activity of miR-200b/a and miR-200c promoters was found in SPRY2-wt cells that express SPRY2 constitutively, whereas transfected ZEB1 expression vector further decreased the activity of the two promoters in Mock cells but not in SPRY2-wt cells (Figure 5h) . Second, ZEB1 and SPRY2 expression vectors were transiently transfected in SW480-ADH cells. Exogenous SPRY2 did not change the activity of the two miRs promoters and did not affect their inhibition by ZEB1 (Figure 5i, left) . These results agree with the reported direct inhibition of miR-200b/a and miR-200c promoters by ZEB1 and suggest that the effect of SPRY2 is mediated by the upregulation of ZEB1, which does not take place at sufficient level upon transient SPRY2 transfection (Figure 5i, right) .
Next, we studied putative mediators of the upregulation of ZEB1 by SPRY2. Given the relation between SPRY2 and EGF signaling, 3, 4 this pathway was chosen for detailed study. In concordance with other reports, 41 SPRY2-wt did not change the basal or EGF-induced levels of active (phosphorylated) ERK (Figure 6a ), which may be related to the presence of a mutated K-RAS gene in SW480-ADH cells. By contrast, SPRY2 amplified the activation of AKT induced by EGF (Figure 6b ). In addition, reduction of active phospho(p)-AKT, using wortmannin (phosphatidylinositol 3 kinase inhibitor) or MK2266 (AKT inhibitor) decreased the level of ZEB1 (Figure 6c) . Similarly, the Src inhibitor PP2 decreased ZEB1 expression in Mock and SPRY2-wt cells and increased that of claudin-7 in Mock cells (Figure 6d) . Thus, AKT and Src seem to participate in the upregulation of ZEB1 by SPRY2.
ETS1 mediates the upregulation of ZEB1 by Snail1 in mouse breast epithelial cells, 42 and our transcriptomic analysis revealed that the RNA level of ETS1 transcription factor is 1.62-fold higher in SPRY2-wt cells than in Mock cells, whereas no differences were found for ETS2 (Supplementary Table 2 ). Therefore, we investigated its implication in SPRY2 action. First, we confirmed by western blot analysis the presence of higher level of ETS1 protein in SPRY2-wt and SPRY2-Y55F cells than in Mock and SPRY2-S112A cells (Figure 6e) . Second, transduction of SPRY2-wt cells with lentiviruses encoding ETS1 shRNA led to a partial reduction of ZEB1 protein expression levels (Figure 6f ). Third, in contrast, ETS1 expression was unaffected by ZEB1 knock-down in SPRY2-wt cells showing that no reciprocal regulation exists (Figure 6g) . Fourth, overexpression of ETS1 by transient transfection of an exogenous complementary DNA increased ZEB1 expression (Figure 6h ). These results suggest that ETS1 contributes to the induction of ZEB1 by SPRY2, which is most likely amplified by the repression of miR-200 and miR-150 species (Figure 6i ).
DISCUSSION
This study shows that SPRY2 triggers a coordinated pattern of gene expression through the imbalance of the ZEB1/miR200 switch in favor of ZEB1 upregulation mediated at least in part by ETS1 and AKT. This mechanism leads to the loss of polarized and adhesive epithelial phenotype.
Tight junctions are responsible for epithelial barrier function and polarity, and control cell proliferation and differentiation, which are disrupted at early and advanced stages of tumorigenesis. 43 In particular, downregulation of claudin-7 is an early event in colorectal cancer 44 and promotes tumorigenesis of colon cancer cells. 45, 46 Data obtained in biopsies from colon cancer patients indicating an inverse relation between ZEB1 and claudin-7 expression are consistent with the downregulation of many tight junction and polarity genes by SPRY2 in SW480-ADH cells. In addition, they agree with the tumorigenic role of ZEB1 and the inverse relation between claudin-7 and other family members and ZEB1 in lung cancer. 47 Altogether, our results showing repression of tight junction proteins by SPRY2 strongly support a protumorigenic action in colon cancer.
Notably, mutation of Ser 112 residue (SPRY2-S112A cells) abolishes most SPRY2 effects on the expression of epithelial genes. The role of this amino acid in SPRY2 activity is controversial. One study has proposed that Ser 112 phosphorylation by Mnk1, a kinase activated by p38MAPK, stabilizes Spry2 protein in Chinese hamster ovary (CHO)-K1 cells. 23 In contrast, another study shows that Mnk2 (also a p38MAPK substrate) but not Mnk1 phosphorylates SPRY2 leading to its association with the E3 ubiquitin ligase Nedd4 and posterior degradation in HEK293T cells. 24 Similarly, p38MAPK decreases Spry2 content in mouse embryo fibroblasts via phosphorylation of Siah2 E3 ubiquitin ligase. 48 Our results agree with this study as the p38MAPK inhibitor SB203080 increased the level of SPRY2 protein in Mock cells (data not shown). In addition, our data agree with those of Edwin et al. 24 regarding the similar effects of wild-type and Tyr 55 SPRY2 proteins. Mutation of Tyr 55 , which has been proposed to generate a 
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dominant-negative SPRY2 in terms of inhibition of fibroblast growth factor signaling, [21] [22] [23] did not affect the repression of tight junction or polarity proteins (SPRY2-Y55F cells), indicating that this residue is important for only a subset of SPRY2 actions.
The precise mechanism by which SPRY2 regulates gene expression is not fully known. We analyzed the expression of the homeobox SIX1 gene, which is overexpressed, in colorectal cancer and promotes EMT at least in part via the repression of SPROUTY-2 induces ZEB1 and EMT in colon cancer cells A Barbáchano et al miR-200 family and activation of ZEB1. 49 No differences were detected (Supplementary Figure S4) . By contrast, the longer activation of AKT and the effect of AKT and Src inhibition on ZEB1 induction suggest that these two enzymes are implicated in SPRY2 action in SW480-ADH cells that, of note, overexpress EGF and harbor a mutated K-RAS gene. AKT and Src may contribute to upregulate ETS1, which in turn activates ZEB1. 42 In conclusion, our findings support a key role of SPRY2 promoting the EMT process in colon carcinoma cells through ZEB1 induction by a mechanism that implies AKT/Src, ETS1 and miR200/miR-150 species (Figure 6i) . Why SPRY2 has, instead, tumor-suppressor activity in other types of cancer cells remains to be elucidated.
MATERIALS AND METHODS
Cells and cell culture
Human colon carcinoma SW480-ADH and HEK293T embryonal kidney cell lines were cultured in RPMI and Dulbecco's modified Eagle's medium plus 10% fetal bovine serum, respectively (Life Technologies, Carlsbad, CA, USA). Cell lines were originally obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and authenticated using the GenePrint 10 System (Promega, Madison, WI, USA), which allows co-amplification and three-color detection of 10 human loci: TH01, TPOX, vWA, Amelogenin, CSF1PO, D16S539, D7S820, D13S317, D21S11 and D5S818. Short tandem repeat profiles were sent for comparison against cell line databases (ATCC, DSMZ). Last test was done in February 2014. SPRY2-wt, SPRY2-S112A and SPRY2-Y55F and Mock cells were generated by stable transfection of SW480-ADH cells with pCEFL-KZ-AU5, pCEFL-KZ-AU5-hSPRY2, pCEFL-KZ-AU5-hSPRY2 S112A or pCEFL-KZ-AU5-hSPRY2 Y55F plasmids. 50 Cells were tested routinely to ensure there was no mycoplasma contamination (Universal Mycoplasma Detection kit, ATCC; #30-1012).
Antibodies and reagents
We used primary mouse monoclonal antibodies against E-cadherin (BD Transduction Laboratories, Franklin Lakes, NJ, USA; #610182), AU5 (Covance, Princeton, NJ, USA; MMS-135R), S6 ribosomal protein (Cell Signaling, Danvers, MA, USA; #23175) and p-ERK (Santa Cruz Biotechnology, Dallas, TX, USA; sc-7383); rabbit polyclonal antibodies against SPRY2 (Upstate, Billerica, MA, USA; #07-524), ETS1 and ERK 2 (Santa Cruz Biotechnology; sc-350 and sc-154 respectively), ZEB1 (Sigma-Aldrich, St Louis, MO, USA; #HPA027524), ST14 (Bethyl, Montgomery, TX, USA; A300-221A), p-AKT (Ser473) (Cell Signaling; #9271), occludin, claudin-7 and claudin-1 (Life Technologies; #71-1500; #34-9100; #51-9000), EpCAM (Abcam, Cambridge, UK) and p-S6 ribosomal protein (Ser240/244) (Cell Signaling; #2215S); and goat polyclonal antibodies against ZEB1, AKT, β-actin and lamin B (Santa Cruz Biotechnology; sc-10572, sc1618, sc-1616 and sc-6216, respectively). Horseradish peroxidase-conjugated secondary antibodies were anti-rabbit IgG (H+L) (Jackson Immunoresearch, West Grove, PA, USA; 111-035-045), anti-mouse IgG (H+L) (Promega; W402B) and anti-goat IgG (Santa Cruz Biotechnology; sc-2020). Secondary antibodies used for Odyssey Infrared Imaging were IRDye 800 donkey anti-mouse IgG (H&L) (Rockland Inc., Gibertsville, PA, USA; #610-732-124) and IRDye 680 donkey anti-rabbit IgG (Rockland Inc.; #926-32223). Inhibitors: Src-family tyrosine kinases, PP2 (Tocris, Bristol, UK, #1407); phosphatidylinositol 3 kinase inhibitor, wortmannin (Cell Signaling; #99516), AKT inhibitor, MK2266 (Selleckchem, Munich, Germany; #S1078).
Cloning of CLDN7/claudin-7 promoter A 1.56-kb fragment of the hCLDN7/Claudin-7 promoter (-1136/+428) similar to the one described by Kohno et al. 51 was amplified by PCR using human genomic DNA as template, and the following primers: forward 5′-GACAAGGAGTGAAACAGG-3′ and reverse 5′-TTCCGCCCTCAGAAAACA-3′. The resulting product was cloned into the pGEM-T Easy vector (Promega) and sequenced. Subsequently, it was released with EcoRI, filled-in using the large fragment of Escherichia coli DNA polymerase I (Klenow), and subcloned into the SmaI site of promoterless pGL3 basic Firefly luciferase expression vector (Promega).
Reporter assays
Reporter assays were performed in SW480-ADH, Mock, SPRY2-wt and HEK293T cells. Unless otherwise indicated, cells were transfected using the jetPEI reagent (PolyPlus Transfection, New York, NY, USA). Firefly (Luc) and Renilla reniformis luciferase (Rluc) activities were measured separately using the GloMax 96 Microplate Luminometer (Promega). Luc activity was normalized to the Rluc activity (constitutive expression). The promoter constructs for miR-200b/a and miR-200c were generously provided by Professor Gregory Goodall (Center for Cancer Biology, Adelaide, Australia) and Professor Thomas Brabletz (University of Freiburg, Germany), respectively. pCDNA3-ZEB1 expression plasmid was provided by Dr Antonio García de Herreros (Instituto Municipal de Investigación Médica, Barcelona, Spain). The results are represented as the average of the fold induction obtained from three independent experiments using quadruplicates.
3′-UTR luciferase assays
A portion of the ZEB1-RNA-3′UTR containing the studied putative miRNAbinding sites was amplified by PCR using the primers forward 5′-CTCGAG CA;CAAAATAAATCCGGGTGTG-3′ and reverse 5′-GCGGCCGCAGTCCCTGCA ATCAGAACTCA-3′, and cloned into psiCHECK2 luciferase reporter vector (Promega) using XhoI and NotI. HEK293T cells were seeded into 96-well plates (20 × 10 3 cells per well) and co-transfected (Lipofectamine 2000, Life Technologies) with the ZEB1-RNA-3'UTR construct and the indicated amounts of mimic negative control (scrambled), miR-200b, miR-142-3p, miR-23a and miR-150 miRIDIAN mimics (Dharmacon, GE Healthcare, Pittsburg, PA, USA). Luciferase activity was measured 24 h later using the Dual-Glo Luciferase Assay System (Promega). Rluc activity was normalized to corresponding Luc activity and plotted as a percentage of the control. Mutations at the putative miRNA-binding sites were generated using the QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. Luciferase assays were performed at least three times using triplicates.
RNA interference and overexpression strategies
ZEB1 knock-down in Mock cells was performed as described.
52 ZEB1 and ETS1 silencing in Mock and SPRY2-wt cells was carried out using the lentiviral vector pGIPz containing different shRNA mir sequences: ZEB1, V3LHS_356186 (sh1), V3LHS_356187 (sh2) and V2LHS_226625 (sh3); ETS1, V2LHS_244928 (sh1) and V3LHS_301171 (sh2) (Dharmacon, GE Healthcare). Non-silencing shRNA mir sequence (NS), with no homology to known mammalian genes was used as control, cloned in pGIPz vector (Dharmacon, GE Healthcare). Lentiviruses were produced and tittered as previously described, 53 and target cells were transduced at multiplicity of infection of 40. ETS1 overexpression in SW480-ADH cells was performed by transient transfection of exogenous ETS1 complementary DNA (OriGene, Rockville, MD, USA; #RG227466).
Quantitative RT-PCR Total RNA was purified using the NucleoSpin miRNA extraction kit (Macherey-Nagel, Düren, Germany). qRT-PCR analyses of SPRY2 (Hs00183386_m1), CDH1 (Hs01023894_m1), CLDN1 (Hs00221623_m1), CLDN7 (Hs00600772_m1), ESRP1 (Hs00214472_m1), INADL (Hs00195106_m1), LLGL2 (Hs00189729_m1), OCLN (Hs00170162_m1), ST14 (Hs01058386_m1) were performed using the TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA, USA). RNA expression values were normalized vs the housekeeping gene RPLPO (large ribosomal protein). The reaction was performed in a CFX384 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). qRT-PCR analyses of hsa-miR-200b 002251, -200c 002300, -142-3p 000464, -23a 000399, -150 000473 and -342-3p 002260 were performed by using miRNA-specific TaqMan MicroRNA Assay Kit (Applied Biosystems). RNU44 001094 small RNA was used for normalization of input RNA/complementary DNA levels. ZEB1 expression was analyzed by using primers forward 5′-GCCAATAAGCAAACGATTCTG-3′ and reverse 5′-TTTGGCTG GATCACTTTCAAG-3′. Values were normalized vs housekeeping gene succinate dehydrogenase complex subunit A (SDHA), forward 5′-TGGGAACAA GAGGGCATCTG-3′ and reverse 5′-CCACCACTGCATCAAATTCATG-3′. All experiments were performed at least three times using triplicates.
Western blot
Western blot was performed as previously described. 7 Proteins were analyzed by using the Odyssey Infrared Imaging or revealed following the ECL technique (Amersham, Buckinghamshire, UK). Different exposure times of the films were used to ensure that bands were not saturated. Western blots in all figures correspond to a representative experiment of at least three performed. Quantification of the experiments is indicated in each figure.
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Immunofluorescence and confocal microscopy Tissue microarrays corresponding to human colorectal (CRC) tumors at stage III, from a collection available in the Pathology Service of the Vall d´Hebron Hospital, were chosen as the protein markers evaluated could potentially have predictive value on cancer progression. Previous data in CRC indicate that the probability of SPRY2 expression is around 0.90. If the probability of SPRY2-mediated ZEB1 overexpression exposure among cases is 0.80, we will need to study 33 cases patients to be able to detect the association between SPRY2 and ZEB1, with a power of 0.90 and two-sided error of 0.05. We used an uncorrected χ 2 statistic to evaluate this hypothesis (PS Power and Sample Size Calculation, Nashville, TN, USA). Tissue microarrays were prepared and immunolabeled as described elsewhere. 54 Briefly, antigens were retrieved by microwaving in 10 mM citrate buffer (pH 6.0) for 10 min and permeabilized with 0.2% Triton X-100 (Sigma-Aldrich). Nonspecific binding was blocked by incubating the sections in 10% bovine serum albumin (Sigma-Aldrich) for 1 h. Cell imaging was performed on a Leica TCS SP5 DMI6000 microscope (Leica Microsystems, Wetzlar, Germany) using argon ion (488 nm), HeNe (543 nm) and violet diode (405 nm) lasers. Images were acquired sequentially by direct register using Leica Confocal Software (LAS AF). Fluorescence image data were analyzed with the MBF 'ImageJ for Microscopy'-program collection of plugins (www.macbiophotonics.ca), using criteria described earlier. 55 Briefly, we defined regions of interest (ROI) in images of immunostained tissues encompassing only tumoral tissue. First, using ImageJ software (Image J, Bethesda, MD, USA), we obtained the integrated density value and each channel-molecule (SPRY2, red channel; ZEB1 or claudin-7, green channel) and Hoechst 33342 (blue channel) for each ROI. Next, we measured the integrated density for Hoechst signal present in each ROI and normalized by a standard nucleus signal, defined as the average integrated density of 10 nuclei taken at random 
Gene expression analysis
Microarray analyses were performed using RNAs obtained from Mock, SPRY2-wt, SPRY2-S112A and SPRY2-Y55F cells in three independent experiments performed in triplicate. Total RNA was extracted following the manufacturer's instructions (Macherey-Nagel). RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Total RNA samples were then processed for hybridization on Gene Chip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) using standard Affymetrix protocols at the Genomics and Proteomics Facility of Centro de Investigación del Cáncer (Salamanca, Spain). Scanning was performed using GeneChip System of Affymetrix (GeneChip Hybridization Oven 640, GeneChip Fluidics Station 450 and GeneChip Scanner 7G). The robust microarray analysis algorithm was used for background correction, intraand inter-microarray normalization, and expression signal calculation. 56 The absolute expression signal for each gene was calculated for each microarray. The expression signal was calculated using the CDF package called GeneMapper from GATExplorer (genemapperhumangene1.0cdf; see webite: http://bioinfow.dep.usal.es/xgate/mapping/mapping.php), 57 which maps into an updated version of human genes, instead of using the original probe-set definition provided by Affymetrix. This mapping provides an improvement thanks to the re-annotation to updated gene loci and removal of cross-hybridation noise. 57 It also allows us to operate from the beginning using gene identification (Ensembl IDs) instead of probe sets (Affymetrix IDs). Mapping to genome version Ensembl v57 (assembly GRCh37) was used for these analyses.
Analysis for differential expression was performed using the R platform for statistical analysis, 58 and several packages from the Bioconductor project 59 (http://www.bioconductor.org/). The raw data were imported into R and preprocessed using the affy package and the robust multichip average method. Further, Pearson correlation test and principal component analysis were carried out with all genes included in the data set. To identify differentially expressed genes, we used the limma package. Correction for multiple testing was accomplished by controlling the false discovery rate using published methods (false discovery rate = 0.1). 60 The experimental settings and raw data obtained in this experiment are deposited in GEO (accession number GSE56941).
Functional enrichment analysis
Single enrichment analysis was performed with differentially expressed genes between conditions. This analysis was carried out with the functional annotation tool included in the DAVID Bioinformatics Resources. We considered only pathways with a Benjamini P-value o0.05 for the KEGG, REACTOME and GO-biological process databases. We used GSEA 61 (www.broadinstitute.org/gsea) to assess the degree of association between our signature (expression data set) and some other signatures previously defined with genes significantly enriched in adhesion (gene sets: REACTOME Adherens_junctions_interactions, GO: 0005911 Intercellular junctions, GO: 0030054 Cell_junctions, KEGG Adherens junctions, KEGG tight junctions, KEGG gap junctions). GSEA requires ranking genes according to their association with a given phenotype, and determining whether genes in a signature tend to present either high (positively enriched) or low ranks (negatively enriched). The output of GSEA is an enrichment score, a normalized enrichment score, which accounts for the size of the gene set being tested, a P-value and an estimated false discovery rate. Enrichment score, normalized enrichment score and false discovery rate were obtained as proposed previously. 61 
Statistical analysis
Statistical analysis was performed using GraphPad Instat (GraphPad Software, San Diego, CA, USA). All experiments and qRT-PCR analyses were performed at least three times using triplicates. Significant differences between groups, expressed as mean ± s.e.m., were calculated by parametric one-way analysis of variance using Tukey-Kramer post-test, and correlation coefficients (r) were calculated by non-parametric Spearman's test. Homogeneity of variances between groups was analyzed using Brown-Forsythe test (not significant (NS) P40.05). The single asterisk indicates Po0.05, the double asterisk Po0.01 and the triple asterisk Po0.001. P40.05 were considered not significant.
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